Treatment of Cognitive Impairment in Schizophrenia
Log in for full access to this session if you are registered.
Registration Options
Session Summary
Impairments in everyday functional outcomes are very common in people with schizophrenia and these impairments are associated with deficits in cognitive functioning. Cognitive enhancement has been proposed as a pathway to disability reduction. This pathway has been clearly defined in terms of the required clinical trials methods, with primary (cognitive) and secondary (functional) outcome measures well validated. Second generation (Newer, Atypical) antipsychotic medications have been thoroughly evaluated with their cognitive enhancement potential.
The results of the large scale CATIE trial found modest benefits for atypical medications, consistent with practice effects. Other research has found that certain subpopulations of patients experience benefit from treatment with these medications, in that patients with better overall clinical response and reasonable adherence to treatment experience greater gains. Other pharmacological strategies for cognitive enhancement have been tested and cognitive enhancing treatment interventions have been developed and tested as well. Future directions clearly include use of atypical medications as a platform, with cognitive enhancement training and pharmacological cognitive enhancement added to this intervention.
Registrant Resources
Sorry, but you are not an authorized user. Please register for the course at the top of this page.
Faculty Information
Dawn Velligan, PhD
View biographical information and disclosuresLearning Objectives
- Discuss characteristics of patients most vulnerable to cognitive change.
- Define improvement in cognition with pharmacological treatment.
- Examine the impact of atypical antipsychotics on cognitive impairment.
- Analyze literature on other treatment options for cognitive impairment.
- Compare treatment options and formulate a treatment algorithm.
Continuing Education Credit
Activity Dates: 04/21/2010 - 04/21/2013
ACPE Contact Hours: 1.0
ACPE Number: 0284-0000-10-016-H01-P (Knowledge)
Nursing Credit Reminder: Note that ACPE and ACCME credit is accepted for certification renewal.
The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This self-study course provides 1.0 contact hours (0.10 CEUs) of knowledge-based continuing education credit from CPNP approved programming. The ACPE universal program number assigned to this course is 0284-0000-10-016-L01-P (1.0 contact hours).
ACPE approved contact hours are accepted for ANCC Certification Renewal (see pages 5 and 6): At least 50% (37.5 hours) of your 75 continuing education hours must be formally approved continuing education hours. Formally approved continuing education hours meet one or more of the criteria listed below:
- Continuing nursing education (CNE) approved for nursing contact hours by an accredited provider or approver of nursing continuing education
- Continuing medical education (CME) approved for CME hours
- Sponsored by organizations, agencies, or educational institutions accredited or approved by the American Nurses Credentialing Center (ANCC) or the Accreditation Council for Continuing Medical Education (ACCME) or the Accreditation Council for Pharmacy Education (ACPE) or the Commission on Dietetic Registration
Course Requirements
This course is provided online at cpnp.org and consists of the speaker audio and slides. A PDF file of the slides is also provided and access is available to participants indefinitely although ACPE credit is available only through the course expiration date.
Participants in this course must complete an examination and achieve a score of 60% or greater. Successful completion of the course also requires the completion of a course evaluation. ACPE statements of credit can be retrieved by participants online at cpnp.org immediately upon successful completion of the course.
- Internet Explorer 6+, Firefox 2+ or Safari 3+
- 1024x768 resolution or greater
- Adobe Flash Player 8+
- 512MB RAM
- Any Operating System capable of the above requirements
- Internet Explorer 7+, Firefox 3+ or Safari 3+
- 1280x768 resolution or greater
- Adobe Flash Player 10+
- Windows XP/2000/Vista and Mac OS 10.4 or better
- 512MB of RAM for Windows XP or Mac OS
- 1GB of RAM for Windows Vista
Minimum:
Recommended:
Target Audience
If you are a pharmacist, nurse practitioner or other healthcare professional involved in the medication therapy management of psychiatric and/or neurological patients, we invite you to participate in this online course.
Grant Support
This programming was supported in part by grants from Bristol-Myers Squibb, Otsuka America Pharmaceutical, Inc., Lilly USA, LLC, AstraZeneca and Cyberonics.